Phone: 888-558-5227

651-644-8424

888-558-7329 Fax: Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID R183731 CAS No. 144875-48-9

Chemical Name 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-

methylpropan-2-ol

Synonym R-848, R848, S28463, alpha-dimethyl-1H-imidazo(4,5-c)

quinoline-1-ethanol.

Formula C₁₇H₂₂N₄O₂ Formula Wt. 314.39

Melting Point

Purity ≥98%

Solubility Soluble in DMSO (100 mM),

ethanol (50 mM), 100% or 5% methanol, and dichloromethane.

Insoluble in water.

Store Temp -20°C

Ship Temp Ambient

Description Resiquimod is an imidazoquinoline compound that is a TLR7/8 agonist. Resiquimod has been shown to activate dendritic cells in

both healthy and inflamed skin, making it effective to induce regression of cutaneous T-cell lymphoma lesions. BALB/c mice treated with resiquimod showed high levels of resistance against parasitic infection. Furthermore, resiquimod has been shown

to produce cardioprotective effects in anoxia-regeneration injuries of neonatal cardiomyocytes.

OH

Bulk quanitites available upon request

Product ID	Size
R183731	5 mg
R183731	10 mg
R183731	25 mg
R183731	50 mg

References Rook AH, Gelfand JM, Wysocka M, et al. Topical resiguimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015 Sep 17;126(12):1452-1461. PMID: 26228486.

> Craft N, Birnbaum R, Quanquin N, et al. Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice. Clin Vaccine Immunol. 2014 Sep;21(9):1314-1322. PMID: 25030052.

> Wang YY, Liu S, Lian F, et al. Toll-like receptor 7/8 agonist resiquimod induces late preconditioning in neonatal cardiac myocytes. Acta Pharmacol Sin. 2011 May; 32(5):565-572. PMID: 21516132.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.